Amicus Therapeutics, Inc.

316 articles with Amicus Therapeutics, Inc.

• Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020

  10/22/2020

  Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2020.

• Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society

  10/12/2020

  Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease

• Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene TherapyAdditional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October

  9/24/2020

  Amicus Therapeutics announced the European Medicines Agency has granted Priority Medicines designation to AT-GTX-501, the Company’s investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 disease, also known as CLN6 Batten disease.

• Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020

  9/3/2020

  Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:

• Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

  8/10/2020

  Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of  $250M-$260M AT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on Schedule Advancing Industry-Leading Rare Disease Gene Therapy Portfolio Path to Profitability Achieved without the Need for Any Future Dilutive Financings Conference Call and Webcast Today at 8:30 a.m. ET

• Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference

  8/4/2020

  Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T.

• Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

  7/28/2020

  Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m.

• Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing

  7/17/2020

  $400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings  Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and Includes Retiring Prior Term Loan Company Reiterates 2020 Galafold Revenue of $250-$260M and 2020 Operating Expense Guidance CRANBURY, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, develop

• Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

  6/4/2020

  Amicus Therapeutics announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held virtually on Wednesday, June 10, 2020 at 8:00 a.m. ET.

• Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders

  5/8/2020

  Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that its 2020 Annual Meeting of Stockholders will now be held solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health and well-being of our employees, stockholders and directors. As p

• Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

  5/7/2020

  Galafold 1Q2020 Revenue of $60.5 Million Reflects Continued Strong Adoption in All Key Global Regions, On Track to Achieve 2020 Revenue Guidance of $250M-$260M

• UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

  5/6/2020

  Amicus Therapeutics a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases announced the acceptance of several abstracts for presentation at the American Society of Gene & Cell Therapy 23rd Annual Meeting being held virtually on May 12 – 15.

• Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

  5/5/2020

  Amicus Therapeutics a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases announced the acceptance of several abstracts for presentation at the American Society of Gene & Cell Therapy 23rd Annual Meeting being held virtually on May 12 – 15.

• Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020

  4/24/2020

  Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 7, 2020 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2020. The call will be led by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus senior leadership team. Interested participants and investors may a

• Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

  3/23/2020

  Amicus Therapeutics announced that the Company has proactively taken numerous measures in response to the novel coronavirus pandemic to support the rare disease community globally and to ensure the achievement of its 2020 key strategic priorities.

• Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia

  3/5/2020

  Amicus Therapeutics (Nasdaq: FOLD) today announced the official opening of the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia to advance its industry leading portfolio of rare disease gene therapy programs

• Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates

  3/2/2020

  Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019.

• Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

  2/26/2020

  CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 8:40 a.m. ET. A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations , and will be ar

• Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020

  2/19/2020

  CRANBURY, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2019. The call will be led by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus senior leadership team. Interested participants and investors may acc

• Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020

  2/7/2020

  CRANBURY, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its development programs for Lysosomal Disorders will be included at the 16th Annual WORLD Symposium ™ 2020 , to be held February 10-13, 2020 in Orlando, FL. Oral Platform Presentations: Ba